Product Development to Business

Exploration-discovery phase Development phase Commercialization and business phases 

The development stories of numerous products are not well recorded or are completely lost. We are grateful that there are a few stories that have received attention from the innovators who took pains to record their stories. 

---

Micro-scaling or bottom up approach to quality costs, where it is possible to calculate the cost of losses involved in manufacture and due to returns and/or claims. This method requires a great deal of experience and relies on the availability of detailed cost data throughout a product s life-cycle. While this is a crucial activity for a business, it is also not a practical approach for estimating the quality cost for product in the early stages of product development. 

The importance of time to market has recently been shown to be responsible for over 30% of the total profit to be made from a product during its life-cycle. However, it has been found that nearly 30% of product development programmes overran their planned times (Maylor, 1996 Nichols et al., 1993). The reduction in profit due to late delivery of the product to market is shown in Figure 5.1 for a sample of businesses surveyed. 

To improve customer satisfaction and business competitiveness, companies need to reduce the levels of non-conformance and attendant failure costs associated with poor product design and development. Attention needs to be focused on the quality and reliability of the design as early as possible in the product development process. This can be achieved by understanding the potential for variability in design parameters and the likely failure consequences in order to reduce the overall risk. The effective use of tools and techniques for designing for quality and reliability can provide this necessary understanding to reduce failure costs. 

Use the data to derive the business, product development, and quality plans for current and future products and services. 

Given the scope and impact of formulated products, tools are needed to help chemical choosers - whether product developers or purchasers - to identify chemicals with desirable characteristics from the hazard perspective and to determine how the use of a particular chemical will affect the overall hazard profile or greenness of a product. We focus in particular on pubhcly available tools and resources that can support small businesses who may not have extensive environmental health and safety resources but who seek to green their chemical products and inventories. 

When the users are not the developers, a major mismatch can result between the material design and the end use. Thus, the developer will have extensive product application development to do, which is both expensive and time-consuming. Initial market potentials can be small, and manufacturing capital costs can be high. Thus, the development of new performance materials as the foundation of a materials business does not look very attractive to materials suppliers. Yet, these enabling technologies are very important to the future development of many basic industries. Some models for the successful development of advanced-performance materials are the following ... 

The N-Zyme Biotec business model unites three areas synergistically (i) strategic alliances in R D, (ii) a module-based services system for the manufacture and modification of proteins, and (iii) product development. Mainly oriented to the Health Sector, its capabilities could be extended to other industries. 

Unitika is a Petrochemical company created in 1889 and which has grown especially into the textile business. Today, their business covers a wide range of economical areas, including financial activities. Its environmental division provides facilities for water treatment, incinerators, air pollution prevention facilities and heavy metal fixing agents. Their R D center conducts research to develop new business areas and products in four segments polymers, environment, advanced materials, and health. 

Problem definition A colleague from the cookies product development department of your company has come to your office to describe what appears to be a significant business issue. Complaints of an off-flavor in your chocolate chip cookies, sold throughout the country, are being reported. Samples of the product are being shipped from the plant by overnight air. Production has been stopped. A recall of all product is under consideration Identification of the off-flavor and its cause are now your top priority ... 

BASF is thus currently endeavouring to establish the substance DINCH as a new registered substitute (entirely tested plasticiser without any hazardous properties) for DEHP in high-price market segments (e.g. medical devices). Soft PVC users substitute on the material level, if they can achieve further process-related and/or quahty-related optimisations in the course of technological development (e.g. underbody hard shells) Environment and health-compatible substance properties are additional qualities in business-to-business (B2B) markets. They are of relevance almost only for manufacturers, who market their products on demand-dominated, saturated markets with differentiated quality production — Hypothesis 8). 

Other chapters in this book deal with the evolution of the legal controls over medicinal products and the structure of the European Union regulatory systems set up to authorise business activities and dealings in these products, and to enforce the rules and restrictions the law places upon them. This chapter aims to select some specific legal and ethical issues that arise in relation to product development, authorisation and sale and supply both within the United Kingdom and within the context of the European systems. 

The hxed-dollar public subsidy would apply to existing and to future vaccines. For existing vaccines, a higher price would encourage more entry into the vaccine business, more investment in developing improved versions of existing vaccines, and greater investments in production capacity to reduce the probability of supply disruptions. For future vaccines, injection of public funds coupled with the mandate would increase market sizes and prospective returns to R D on new vaccines. 

---